Phase II Randomized Trial of BI 730357, a Novel Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis

By sjmartinez • January 24, 2025

Gooderham MJ, Mrowietz U, Kadus W, Drda K, Gu H, Vangerow H, Flack M, Korell J, Sofen H, Papp KA. Phase II Randomized Trial of BI 730357, a Novel Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis. J Invest Dermatol. 2025 Jan 21:S0022-202X(25)00034-X. doi: 10.1016/j.jid.2024.12.025. Epub ahead of print. PMID: 39848568.

Tags: clinical trials, Cytokines, Dermatology, Inflammatory skin diseases, Olive View DoM, psoriasis, Publications

Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH 3rd, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R,[...]

Exacerbation of bullous systemic lupus erythematosus with erythema gyratum repens-like pattern following dupilumab

Santiago Mangual KP, Truong A, Mo J, Liu J, Khaligi MA, Haussmann A, Razmjou AA, Holland V, Cheng K. Exacerbation of bullous systemic lupus erythematosus[...]

Chronic companions: An updated national cross-sectional study of metabolic syndrome comorbidities in outpatient visits for hidradenitis suppurativa

Ma EJ, Roberts AM, Chou P, Katz A, Jeong CY, Nong Y, Ochoa MT, Armstrong AW. Chronic companions: An updated national cross-sectional study of metabolic[...]